Stock AnalizAdaptive Biotechnologies Corp ADPT
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2019 · data as of November 13, 2026
Adaptive Biotechnologies Corp (ADPT) is a healthcare company listed in the US with a market value of about $4.7B. In the twelve months to September 30, 2026 it had revenue of $298M and net income of -$71M, a net margin of -23.7%.
Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 23% a year, a 5-year average ROIC of -28%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 96% below the current price.
Score: 1.4 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 9 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $298M | $277M | $179M | $170M | $185M | $154M | $98M | $85M | $56M | $38M |
| Net income | -$71M | -$59M | -$159M | -$225M | -$200M | -$207M | -$146M | -$69M | -$46M | -$43M |
| Free cash flow | -$9M | -$49M | -$99M | -$167M | -$200M | -$254M | -$168M | $194M | -$39M | -$37M |
| EPS (diluted) | $-0.45 | $-0.39 | $-1.08 | $-1.56 | $-1.40 | $-1.48 | $-1.11 | $-1.01 | $-3.67 | $-3.50 |
| Net margin | -23.7% | -21.5% | -89.1% | -132.3% | -108.0% | -134.3% | -148.6% | -80.7% | -83.4% | -111.4% |
| ROIC | — | -13.3% | -38.2% | -42.2% | -22.7% | -23.1% | -14.2% | -10.8% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 7 analysts is $32.57, 12% above the current price; targets range from $21.00 to $35.00; the consensus rating is “Strong buy”; expected EPS is $-0.37 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Adaptive Biotechnologies stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 96% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Adaptive Biotechnologies pay a dividend?
Not currently.
Is Adaptive Biotechnologies a good stock to buy?
We do not give buy or sell advice. Adaptive Biotechnologies scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.